Abstract：
OBJECTIVE: Determine the COVID-19 seroconversion rate for patients with multiple myeloma receiving a COVID-19 vaccine.
METHODS: After 45 patients received their second COVID-19 vaccine dose, their serum IgG antibodies were measured: 22 with monoclonal gammopathy (MG) of unknown significance, 3 with smoldering myeloma, 2 with light chain amyloidosis, and 18 with MG (9 in remission, 6 out of remission, and 3 with free light-chain gammopathy alone). A second serum specimen was retained for 16 patients with MG. Their antibody levels were compared to those of 78 uninfected healthy vaccinated control patients.
RESULTS: Three patients with MG had low antibody levels on blood collected 98, 100, and 113 days after the initial vaccine dose (2 with MG of unknown significance and 1 with hypogammaglobulemia). The other 40 patients with MG (seroconversion rate 93%) and both patients with amyloidosis produced antibodies. Relative to days after vaccination, patients with MG had lower antibody levels than control patients.
CONCLUSIONS: After receiving a COVID-19 vaccine, most patients with MG produce anti-SARS-CoV-2 antibodies comparable to levels in uninfected vaccinated healthy control patients.
METHODS: After 45 patients received their second COVID-19 vaccine dose, their serum IgG antibodies were measured: 22 with monoclonal gammopathy (MG) of unknown significance, 3 with smoldering myeloma, 2 with light chain amyloidosis, and 18 with MG (9 in remission, 6 out of remission, and 3 with free light-chain gammopathy alone). A second serum specimen was retained for 16 patients with MG. Their antibody levels were compared to those of 78 uninfected healthy vaccinated control patients.
RESULTS: Three patients with MG had low antibody levels on blood collected 98, 100, and 113 days after the initial vaccine dose (2 with MG of unknown significance and 1 with hypogammaglobulemia). The other 40 patients with MG (seroconversion rate 93%) and both patients with amyloidosis produced antibodies. Relative to days after vaccination, patients with MG had lower antibody levels than control patients.
CONCLUSIONS: After receiving a COVID-19 vaccine, most patients with MG produce anti-SARS-CoV-2 antibodies comparable to levels in uninfected vaccinated healthy control patients.
摘要：
目的：确定接受COVID-19疫苗的多发性骨髓瘤患者的COVID-19血清转换率。
方法：在45名患者接受第二次COVID-19疫苗后，他们的血清IgG抗体进行了测量：22与单克隆丙种球蛋白（MG）的意义不明，3患有闷烧的骨髓瘤，2具有轻链淀粉样变性，18例MG（9例缓解，6个缓解期，和3与单独的游离轻链丙种球蛋白病）。保留了16例MG患者的第二份血清样本。将他们的抗体水平与78名未感染健康接种疫苗的对照患者的抗体水平进行比较。
结果：3例MG患者在初始疫苗剂量后98、100和113天采集的血液中抗体水平较低（2例MG意义不明，1例低丙种血症）。其他40例MG患者（血清转换率93％）和两名淀粉样变性患者均产生抗体。相对于接种疫苗后的天数，MG患者的抗体水平低于对照组.
结论：在接受COVID-19疫苗后，大多数MG患者产生的抗SARS-CoV-2抗体与未感染接种疫苗的健康对照患者的水平相当.
方法：在45名患者接受第二次COVID-19疫苗后，他们的血清IgG抗体进行了测量：22与单克隆丙种球蛋白（MG）的意义不明，3患有闷烧的骨髓瘤，2具有轻链淀粉样变性，18例MG（9例缓解，6个缓解期，和3与单独的游离轻链丙种球蛋白病）。保留了16例MG患者的第二份血清样本。将他们的抗体水平与78名未感染健康接种疫苗的对照患者的抗体水平进行比较。
结果：3例MG患者在初始疫苗剂量后98、100和113天采集的血液中抗体水平较低（2例MG意义不明，1例低丙种血症）。其他40例MG患者（血清转换率93％）和两名淀粉样变性患者均产生抗体。相对于接种疫苗后的天数，MG患者的抗体水平低于对照组.
结论：在接受COVID-19疫苗后，大多数MG患者产生的抗SARS-CoV-2抗体与未感染接种疫苗的健康对照患者的水平相当.
